Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFGND4)

Drug Name
Aminocaproic Acid Drug Info
Synonyms
6-Aminohexanoic acid; 6-aminohexanoic acid; 6-Aminocaproic acid; aminocaproic acid; 60-32-2; amicar; Epsikapron; Caprocid; Capramol; Epsamon; EACA; Caprolisin; Acepramin; Hemocaprol; Epsicapron; Respramin; Amikar; EPSILON-AMINOCAPROIC ACID; Hexanoic acid, 6-amino-; Epsilcapramin; Aminokapron; Caplamin; Acepramine; Capracid; Hemopar; Ipsilon; Afibrin; Atsemin; Hepin; Epsilon S; Aminocaproic; Capralense; epsilon-Leucine; EACS; epsilon-Norleucine; epsilcapramine; 6-Amino-n-hexanoic acid; omega-Aminocaproic acid; epsilon-Aminohexanoic acid; 6-amino-hexanoic acid; ACS; Amicar; Aminocaproate; Capranol; Caproamin; Epsicaprom; Epsilcapramine; Hemopar;Hepin; Acide aminocaproique; Acide aminocaproique [French]; Acide aminocaproque; Acido aminocaproico; Acidum aminocaproicum; Acidum aminocaproicum [Latin]; Aminocaproic Acid In Plastic Container; Aminocaproic Acids; Aminohexanoic acid; Eaca kabi; Epsilon Aminocaproic Acid; A 7824; CL 10304; CY 116; CY116; JD 177; Acide aminocaproique [INN-French]; Acido aminocaproico [DCIT,Spanish]; Acido aminocaproico [INN-Spanish]; Acidum aminocaproicum [INN-Latin]; Amicar (TN); Aminocaproic acid (USP); CL-10304; CY-116; Epsilon-Ahx; Epsilon-Aminocaproic acid; Epsilon-Aminocapronsaeure; Epsilon-Aminohexanoic acid; Epsilon-Leucine; Epsilon-Norleucine; Epsilon-aminocaproate; Epsilon-aminocapronzuur; Fullevir (TN); Kyselina omega-aminokapronova; Kyselina omega-aminokapronova [Czech]; Omega-Aminocaproic acid; Omega-Aminohexanoic acid; S04-0132; Acid, 6-Aminocaproic; Acid, 6-Aminohexanoic; Acid, epsilon-Aminocaproic; Aminocaproic acid (USP/INN); Aminocaproic acid [USAN:BAN:INN]; Aminocaproic acid [USAN:INN:BAN]; Epsilon-Aminocaproic acid (JAN); HEXANOIC ACID,6-AMINO; Epsilon-Amino-n-caproic acid; Epsilon-Amino-n-hexanoic acid; Amicar, A-amino caproic acid, A-Ahx, 6-aminohexanoic acid, Aminocaproic acid; 6 Aminocaproic Acid; 6 Aminohexanoic Acid; 6-amino-n-caproate; 6-amino-n-caproic acid; 6-aminohexanoate; 6-Amino Hexanoic Acid
Indication
Disease Entry ICD 11 Status REF
Bleeding disorder GA20-GA21 Approved [1]
Postoperative hemorrhage NE81.0Z Approved [2]
Therapeutic Class
Antifibrinolytic Agents
Cross-matching ID
PubChem CID
564
ChEBI ID
CHEBI:16586
CAS Number
CAS 60-32-2
TTD Drug ID
DMFGND4
VARIDT Drug ID
DR01014
ACDINA Drug ID
D00030

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tissue-type plasminogen activator (PLAT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine DM3UMYD Discovery agent N.A. Investigative [6]
1-guanidino-N-phenyl-7-isoquinolinesulphonamide DMTF1HL Discovery agent N.A. Investigative [7]
BMS-344577 DM9WRUG Discovery agent N.A. Investigative [8]
N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine DMNO46U Discovery agent N.A. Investigative [9]
5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID DMPFX0S Discovery agent N.A. Investigative [10]
N-(4-Phenyl-pyridin-2-yl)-guanidine DMYD4PC Discovery agent N.A. Investigative [11]
N-(7-Benzyloxy-isoquinolin-1-yl)-guanidine DMPMBC2 Discovery agent N.A. Investigative [9]
N-(5-Benzyloxy-isoquinolin-1-yl)-guanidine DMGAITY Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Targeting Plasminogen (PLG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranolazine DM0C9IL Acute coronary syndrome BA41 Approved [12]
Streptokinase DM5JQ0D Pulmonary embolism BB00 Approved [13]
Tranexamic Acid DMFI8A7 Excessive bleeding GA30.02 Approved [14]
Alteplase DMRJ3YX Acute myocardial infarction BA41 Approved [15]
Tenecteplase DMJYN25 Acute myocardial infarction BA41 Approved [15]
Anistreplase DM6Q4B0 Acute coronary syndrome BA41 Approved [16]
Reteplase DML0D1P Heart attack BA41 Approved [17]
MELAGATRAN DM4W8RE N. A. N. A. Phase 3 [18]
Desmoteplase DMDLU4Z Ischemic stroke 8B11.5Z Phase 3 [19]
Plasminogen DM0EFQS Alzheimer disease 8A20 Phase 2/3 [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Antithrombin-III (SERPINC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [21]
Prednisone DM2HG4X Acute asthma CA23 Approved [5]
Quercetin DM3NC4M Obesity 5B81 Approved [22]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [23]
Testosterone enanthate DMB6871 N. A. N. A. Approved [24]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [25]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [26]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [27]
Warfarin DMJYCVW Atrial fibrillation BC81.3 Approved [28]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Alpha-2-macroglobulin (A2M)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [30]
Prednisone DM2HG4X Acute asthma CA23 Approved [5]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [31]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [32]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [33]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [32]
Acocantherin DM7JT24 Atrial fibrillation BC81.3 Approved [34]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [23]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [25]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [35]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasminogen (PLG) TTP86E2 PLMN_HUMAN Inhibitor [3]
Tissue-type plasminogen activator (PLAT) TTXAGYU TPA_HUMAN Inhibitor [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alpha-2-macroglobulin (A2M) OTFTX90K A2MG_HUMAN Gene/Protein Processing [5]
Antithrombin-III (SERPINC1) OTDFATG0 ANT3_HUMAN Gene/Protein Processing [5]

References

1 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6574).
3 The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5 Plasma proteinase inhibitor activity and hemostasis tests in children with nephrotic syndrome. Effect of prednisone alone and prednisone plus epsilon-aminocaproic acid treatment regimens: a preliminary report. Am J Ther. 2001 Mar-Apr;8(2):97-107. doi: 10.1097/00045391-200103000-00004.
6 Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
7 Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
8 Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9.
9 Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
10 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
11 Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. Bioorg Med Chem Lett. 2002 Jan 21;12(2):181-4.
12 Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
13 Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
14 Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
15 Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
16 Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
17 Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
18 Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
19 Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.
20 Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54.
21 MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
22 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
23 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
24 Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost. 1995 Aug;74(2):693-7.
25 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
26 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
27 Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med. 2003 Apr;31(4):1068-74. doi: 10.1097/01.CCM.0000059646.89546.98.
28 Venous thrombosis, heparin-induced antithrombin III deficiency, and factor VIII. Lancet. 1977 Dec 10;2(8050):1231-2.
29 Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab. 2007 Jun;92(6):2074-9. doi: 10.1210/jc.2007-0026. Epub 2007 Mar 20.
30 Selenium is critical for cancer-signaling gene expression but not cell proliferation in human colon Caco-2 cells. Biofactors. 2007;31(3-4):155-64. doi: 10.1002/biof.5520310302.
31 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
32 Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
33 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
34 Proteomics analysis of the proliferative effect of low-dose ouabain on human endothelial cells. Biol Pharm Bull. 2007 Feb;30(2):247-53. doi: 10.1248/bpb.30.247.
35 Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.